A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary) ; Bevacizumab; Paclitaxel
- Indications Advanced breast cancer
- Focus Biomarker; Registrational; Therapeutic Use
- 24 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 19 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 22 Nov 2010 Planned end date changed from 1 Oct 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.